Targeted Therapy (ASCO TAPUR)

Targeted Agent and Profiling Utilization Registry (TAPUR) 

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

This trial is available at multiple Sutter locations.  Please contact one of the following about ASCO TAPUR

San Francisco: Please contact ClinicalResearch@sutterhealth.org

Palo Alto/Santa Cruz: Please contact Tanya Pozniansky pozniat@sutterhealth.org

East Bay: Please contact James Nasman NasmanJ@sutterhealth.org and Vivian Leong, RN Leongv@sutterhealth.org

Sacramento: Isabel Rodrigues-Fong Rodrigi@sutterhealth.org  and Kirsten Babski babskik@sutterhealth.org 

Modesto: Delia Massone MassonD@sutterhealth.org and Adrienne Palos PalosA@sutterhealth.org 

Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals@sutterhealth.org 

Eligibility Requirements

patients 18 years old and up

Locally advanced or metastatic solid tumor, multiple myeloma, or B cell non-Hodgkin lymphoma 

Principal Investigator

Stacy D'Andre, MD

Recruitment Status

Active, Recruiting

Funder

American Society of Clinical Oncology

Start Date

January 23, 2018